Compare CTXR & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTXR | ASBP |
|---|---|---|
| Founded | 2007 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 12.3M |
| IPO Year | 2010 | 2021 |
| Metric | CTXR | ASBP |
|---|---|---|
| Price | $0.53 | $8.17 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 258.4K | 26.6K |
| Earning Date | 08-14-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.38 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $104.18 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.37 | $3.31 |
| 52 Week High | $1.60 | $367.50 |
| Indicator | CTXR | ASBP |
|---|---|---|
| Relative Strength Index (RSI) | 53.77 | 44.73 |
| Support Level | $0.48 | $7.65 |
| Resistance Level | $0.61 | $8.11 |
| Average True Range (ATR) | 0.05 | 0.62 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 62.85 | 47.32 |
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
Aspire-Lakewood Holdings Inc is a United States-based company. Along with its subsidiary, it is involved in the design and manufacture of engineered automotive and industrial control systems that combine mechanical engineering, electronics, and computer science to provide intelligent, automated systems for vehicle electrification, safety, lightweighting, and sustainability. DCSC maintains a powertrain-agnostic product portfolio that includes mechatronic actuators, human-machine interfaces, industrial cables, and cable control systems backed by over 310 patents. The Company operates around 11 manufacturing facilities globally and serves as a tier-one automotive supplier to OEMs and other industrial firms.